<DOC>
	<DOCNO>NCT00121147</DOCNO>
	<brief_summary>The purpose study compare additive effect eye pressure Azopt Alphagan P Travatan .</brief_summary>
	<brief_title>Additivity Study : Additive Effect Eye Pressure Azopt Alphagan P Travatan</brief_title>
	<detailed_description>The purpose research study compare effect pressure inside eye Brinzolamide Ophthalmic Suspension , 1 % ( Azopt ) , carbonic anhydrase inhibitor , Brimonidine Tartrate Ophthalmic Solution , 0.15 % ( Alphagan-P ) , alpha 2 agonist , add Travoprost Ophthalmic Solution , 0.004 % ( Travatan ) , prostaglandin , patient primary open angle glaucoma , ocular hypertension pseudoexfoliation syndrome . Brinzolamide Ophthalmic Suspension , 1 % ( Azopt ) , Brimonidine Tartrate Ophthalmic Solution , 0.15 % ( Alphagan-P ) , Travoprost Ophthalmic Solution , 0.004 % ( Travatan ) currently approve FDA market , use patient . Even though three medication currently approve purpose study consider study medicine . Glaucoma , Ocular Hypertension Pseudoexfoliation syndrome treat IOP-lowering medication surgery low pressure inside eye reduce risk visual field loss . Today , common treatment patient often begin prescription prostaglandin ( Travoprost ) . If prostaglandin low pressure inside eye enough , second drug usually add . Topical carbonic anhydrase inhibitor ( Brinzolamide ) alpha 2 agonist ( Brimonidine ) common choice additive medicine .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Exfoliation Syndrome</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Minimum age : 35 year Uni bilateral primary open angle glaucoma , ocular hypertension pseudoexfoliation syndrome ( POAG define VF optic nerve change consistent glaucomatous disease ) Insufficient response monotherapy : define IOP &gt; 18mm Hg ( mean diurnal ) less 32 mm Hg Travatan baseline Informed consent HIPPA consent obtain screen visit prior study event Ability adhere study treatment visit plan Closed , occlude , potentially occludable angle History angle closure Previous intraocular surgery , except uncomplicated clear cornea phacoemulsification argon laser trabeculoplasty Argon laser trabeculoplasty phacoemulsification within last 3 month Central corneal thickness outside 500 â€“ 600 ( inclusive ) micron range measure ultrasonic pachymetry Ocular periocular inflammation within 3 month prior study ( except blepharitis relate seasonal allergic conjunctivitis ) History uveitis previous intraocular inflammation ( postoperatively ) Hypersensitivity sulfa , alpha agonist benzalkonium chloride History use steroid 1 week within 3 month screen likely need corticosteroid study ( except inhale , nasal topical nonocular ) Use systemic medication know effect IOP ( e.g . Alpha agonist , Beta blocker , Ace inhibitor angiotensin II receptor blocker ) stable three month prior baseline dosage expect change course study Women Pregnancy ( study medication determine cause possible harm fetus ) Women childbearing potential use contraceptive method . Childbearing potential define woman postmenopausal ( 12 month without menstrual period ) surgically sterile . Contraceptive method define abstinence , vasectomized partner , ongoing use approve oral , injectable , topical implant contraceptive , barrier method IUD General : Use investigational medication within one month prior baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>pseudoexfoliation</keyword>
</DOC>